| About Codal-Synto |
CODAL-SYNTO, THE COMPANY Codal-Synto, established in 1978, is located in Limassol, on the southern shores of Cyprus. Until recently, and before the induction of Cyprus as a full member of the European Union in May of 2004, the company's manufacturing facilities encompassed an area of 1600m^2 which included production and utility areas, quality control laboratories and warehouses.
The increasing demand of our clientele to provide an amplified range of products at higher volumes, combined with our objective to infiltrate further into the European regulated markets has facilitated a strategic contractual agreement with one of the largest players in the region.
Medochemie Ltd., the largest generic pharmaceutical company in region with activities encompassing over 75 countries across the globe, has signed to undertake our product range and under license, manufacture, our items within its modern and EU/GMP approved amenities.
With this arrangement Codal continues to source the generic pharma market with high therapeutically equivalent, established and recognized branded products that our customers have been acquainted to since our establishment in 1978. Even more importantly, due to the arrangement of this accord Codal-Synto has the capacity, owing to lower overhead costs, to offer these quality products at further competitive prices, thus further ensuring the position of the establishment well into the future.
In conjunction with our partners' 11,000^m2 state of the art facilities, and the acquiring of additional product dossiers, in addition to our existing product range, and combined with our access to intellectual property, transform Codal-Synto into a recognized and well established source of high quality generics. With an incomparable range of extensive drug formulations, we are in position to meet several generic pharma requirements, encompassing private, as well as governmental sections, both for regulated and non-regulated markets across all market regions.
Codal is now in position to provide to a broader range of molecules, at higher productions cycles, with lower costs, at more competitive price levels, thus allowing us to keep up with our increased customers' demands, and limitlessly expanding our activities to every possible market. |
 |
|
|
|
